Proliferative retinopathy in Duchenne muscular dystrophy and its response to bevacizumab

Saved in:

Bibliographic Details
Published in	Clinical & experimental ophthalmology Vol. 40; no. 9; pp. 906 - 907
Main Authors	Fagan, Xavier J, Levy, Jaime, Al-Qureshi, Salmaan, Harper, C Alex
Format	Journal Article
Language	English
Published	Melbourne, Australia Blackwell Publishing Asia 01.12.2012 Wiley Subscription Services, Inc
Subjects	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Fluorescein Angiography Humans Intravitreal Injections Male Muscular Dystrophy, Duchenne - complications Retinal Neovascularization - complications Retinal Neovascularization - diagnosis Retinal Neovascularization - drug therapy Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Young Adult
Online Access	Get full text
ISSN	1442-6404 1442-9071 1442-9071
DOI	10.1111/j.1442-9071.2012.02822.x

More Information
Bibliography:	ark:/67375/WNG-JMJC8QDH-N istex:6F13180AAFFA7799E79957C0F0AA9539899FE04D ArticleID:CEO2822 No stated conflict of interest Funding sources Dr Xavier J Fagan is currently employed as a retinal fellow at Royal Victorian Eye and Ear Hospital. The fellowship is sponsored by Novartis. Competing/conflicts of interest ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Report-3 ObjectType-Case Study-4 ObjectType-Case Study-2 ObjectType-Correspondence-3 content type line 23 ObjectType-Article-4 ObjectType-Report-1
ISSN:	1442-6404 1442-9071 1442-9071
DOI:	10.1111/j.1442-9071.2012.02822.x